117437 ⎘
Hydrolases acting on acid anhydrides (3.6) acting on GTP; involved in cellular and subcellular movement (3.6.5) Small monomeric GTPase (3.6.5.2)
PLATELETS TRANSFECTED WITH SIRNA AND THE THERAPEUTICS USES THEREOF
#2T-Cell Modulatory Polypeptides and Methods of Use Thereof
#3ALLOGENEIC DENDRITIC CELL (alloDC) TUMOR VACCINE, AND PREPARATION METHOD AND USE THEREOF
#4COMPOSITIONS AND METHODS FOR TREATING CANCER
#5COMPOUNDS INCLUDING A MUTANT KRAS SEQUENCE AND A LIPID AND USES THEREOF
#6Cell cultivation processes for preparing food products, products provided by said processes and a system for providing these processes
#7COMPOSITIONS AND METHODS FOR TREATING PANCREATIC CANCER
#8IMMUNOGENIC COMPOSITIONS COMPRISING NUCLEIC ACIDS FOR RAS PEPTIDES
#9USE OF RAP2C IN BREEDING OF BLCATTLE BLACK CATTLE
#10ANTIGENS FOR CANCER IMMUNOTHERAPY
#11VIRAL VECTOR AND CANCER CELL PROLIFERATION INHIBITOR COMPRISING THE SAME
#12AUGMENTING CAR T CELL ACTIVITY
#13COMPOUNDS INCLUDING A MUTANT KRAS SEQUENCE AND A LIPID AND USES THEREOF
#14EPITOPE FOCUSING BY VARIABLE EFFECTIVE ANTIGEN SURFACE CONCENTRATION
#15TARGETING MUTANT KRAS WITH A MUTATION SPECIFIC IGA
#16COMPOSITIONS AND METHODS FOR TREATING CANCER
#17COMPOSITIONS AND METHODS FOR TREATING CANCER
#18METHODS OF INDUCING CELL DEATH OF A POPULATION OF SOLID TUMOR CELLS
#19MODIFIED ARENAVIRUS PARTICLES EXPRESSING MUTANT KRAS, MUTATED CANCER DRIVER GENE, OR TUMOR-ASSOCIATED ANTIGEN AS CANCER IMMUNOTHERAPIES
#20COMPOSITIONS AND METHODS FOR ENHANCING GENE SILENCING ACTIVITY OF OLIGONUCLEOTIDE COMPOUNDS
#21COMPOUNDS INCLUDING A MUTANT KRAS SEQUENCE AND A LIPID AND USES THEREOF
#22BIOLOGICALLY STABLE XNAZYME THAT EFFICIENTLY SILENCES GENE EXPRESSION IN CELLS
#23Genetically Engineered Phagocytes, and Related Compositions, Vectors, Methods and Systems
#24EPITOPE PEPTIDE OF RAS G13D MUTANT AND T CELL RECEPTOR RECOGNIZING RAS G13D MUTANT
#25Compositions and methods for treating cancer
#26Compositions and methods for treating cancer
#27PAN-RAS mRNA CANCER VACCINES
#28Epitope focusing by variable effective antigen surface concentration
#29Compositions and methods for treating cancer
#30Compositions and methods for treating cancer
#31POLYNUCLEOTIDES FOR DISRUPTING IMMUNE CELL ACTIVITY AND METHODS OF USE THEREOF
#32IMMUNOGENIC COMPOSITIONS COMPRISING NUCLEIC ACIDS FOR RAS PEPTIDES
#33METHODS AND COMPOSITIONS FOR THE EXPRESSION OF CONSTITUTIVELY ACTIVE RAP1A FROM A VMD2 PROMOTER
#34KRAS VARIANT MRNA MOLECULES
#35METHODS FOR INDUCING FULL ABLATION OF HEMATOPOIESIS
#36METHOD AND SYSTEM FOR PREDICTING COUPLING PROBABILITIES OF G-PROTEIN COUPLED RECEPTORS WITH G-PROTEINS
#37Neoantigen peptide mimics
#38Immunogenic compositions comprising nucleic acids for RAS peptides
#39Compositions and methods for treating cancer
#40Antibodies for prevention, treatment and diagnosis of infection
#41Epitope focusing by variable effective antigen surface concentration
#42Compounds including a mutant KRAS sequence and a lipid and uses thereof
#43Compositions and methods for treating cancer
#44Compositions and methods for treating cancer
#45Epitope focusing by variable effective antigen surface concentration
#46Methods of preparing antibodies
#47COMPOSITIONS AND METHODS FOR TREATING CANCER
#48METHOD FOR SCREENING INHIBITORS OF RAS
#49Epitope focusing by variable effective antigen surface concentration
#50Mice with transgene of iBox peptide inhibitor of group B p21-activated kinases
#51Lateral flow device and method of use
#52Method for treating Huntingtons's disease
#53NRAS related cancer therapy
#54Compositions and Methods For the Modulation of Ras Proteins
#55Compositions and methods for regulating glucose metabolism
#56Method for inhibiting intracellular activated RAS using intact immunoglobulin-type antibody having cytosol-penetrating ability and use thereof
#57Method for screening inhibitors of Ras
#58Fusion proteins for use as immunogenic enhancers for inducing antigen-specific T cell responses
#59Compositions and methods for treating cancer
#60METHODS OF IMPROVING DROUGHT TOLERANCE AND SEED PRODUCTION IN RICE
#61Methods and compositions for neuroprotection
#62Fusion proteins for use as immunogenic enhancers for inducing antigen-specific T cell responses
#63Use of RHOA in cancer diagnosis and inhibitor screening
#64High resolution melting analysis as a prescreening tool
#65Compositions Comprising RAC Mutants, and Methods of Use Thereof
#66Epitope focusing by variable effective antigen surface concentration
#67COMPOSITIONS AND METHODS FOR TREATING CANCER
#68Prevention, treatment and diagnosis of infection
#69Chimeric peptides for the regulation of GTPases
#70Methods and compositions for neuroprotection
#71Method for producing phosphoserine incorporated proteins by using SepRS mutants and EF-Tu mutants
#72Compositions and methods for regulating glucose metabolism
#73Fusion proteins for use as immunogenic enhancers for inducing antigen-specific T cell responses
#74Phenotypic reversion of pancreatic carcinoma cells
#75Chimeric peptides for the regulation of GTPases
#76Screening methods for compounds that modulate ARF-6 mediated endosomal redistribution
#77Prevention, treatment and diagnosis of infection
#78FOCAL CALCIUM CHANNEL MODULATION
#79Chimeric peptides for the regulation of GTPases
#80PHENOTYPIC REVERSION OF PANCREATIC CARCINOMA CELLS
#81Chimeric peptides for the regulation of GTPases
#82RHO Family Antagonists and Their Use to Block Inhibition of Neurite Outgrowth
#83Focal calcium channel modulation
#84Phenotypic reversion of pancreatic carcinoma cells
#85Phenotypic reversion of pancreatic carcinoma cells
#86Elastin prevents occlusion of body vessels by vascular smooth muscle cells
#87Conjugated oligomeric compounds and their use in gene modulation
#88Chimeric peptides for the regulation of GTPases
#89Immunogenic compositions comprising nucleic acids for RAS peptides
#90Method for patient stratification and drug efficacy monitoring
#91Tools to detect, track and target cancer cells in vivo